The first connectable lateral flow tests at Arab Health 2022
Biosynex will present during the show two innovative devices that simplify the diagnosis of SARS-CoV-2: AMPLIQUICK® and LABPAD® Evolution.
United Arab Emirates, 17 January 2022 – The Biosynex group will be present this year at Arab Health 2022 exhibition. The company, which specializes in the design of medical devices, will present innovative solutions to fight covid-19 epidemic.
Biosynex will present during the show two innovative devices that simplify the diagnosis of
SARS-CoV-2: AMPLIQUICK® and LABPAD® Evolution.
The first, BIOSYNEX AMPLIQUICK® enables the detection by RT-PCR of 4 major respiratory viruses. This amplification kit eliminates the extraction step, thus reducing the number of handling operations and saving laboratory technicians valuable time. The AMPLIQUICK® device also enabled the detection of one of the first cases of the OMICRON variant in mainland France.
Thierry Paper, Managing Director stated: “BIOSYNEX has invested heavily in the development of reliable and easy-to-use RT-PCR test solutions. The detection of a first case of the Omicron variant with our kit confirms the quality of our solutions and is a real source of satisfaction for the team. We are currently working to extend our range of molecular biology to support laboratories in their efforts to manage the Covid-19 pandemic.”